These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 15951469)

  • 1. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial.
    Ng CM; Bruno R; Combs D; Davies B
    J Clin Pharmacol; 2005 Jul; 45(7):792-801. PubMed ID: 15951469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H; Mayer PR; Wajdula J; Fatenejad S
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response.
    Breedveld F; Agarwal S; Yin M; Ren S; Li NF; Shaw TM; Davies BE
    J Clin Pharmacol; 2007 Sep; 47(9):1119-28. PubMed ID: 17766699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.
    Zhou H; Jang H; Fleischmann RM; Bouman-Thio E; Xu Z; Marini JC; Pendley C; Jiao Q; Shankar G; Marciniak SJ; Cohen SB; Rahman MU; Baker D; Mascelli MA; Davis HM; Everitt DE
    J Clin Pharmacol; 2007 Mar; 47(3):383-96. PubMed ID: 17322150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis.
    Haringman JJ; Gerlag DM; Smeets TJ; Baeten D; van den Bosch F; Bresnihan B; Breedveld FC; Dinant HJ; Legay F; Gram H; Loetscher P; Schmouder R; Woodworth T; Tak PP
    Arthritis Rheum; 2006 Aug; 54(8):2387-92. PubMed ID: 16869001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of biological variables upon pharmacokinetic parameters of intramuscular methotrexate in rheumatoid arthritis.
    Debord J; Carpentier N; Sabot C; Bertin P; Marquet P; Treves R; Merle L; Lachâtre G
    Int J Clin Pharmacol Ther; 1998 Apr; 36(4):227-30. PubMed ID: 9587050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of infliximab in patients with ankylosing spondylitis.
    Xu Z; Seitz K; Fasanmade A; Ford J; Williamson P; Xu W; Davis HM; Zhou H
    J Clin Pharmacol; 2008 Jun; 48(6):681-95. PubMed ID: 18401017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a Phase I, open-label, dose-escalation clinical study.
    Burge DJ; Bookbinder SA; Kivitz AJ; Fleischmann RM; Shu C; Bannink J
    Clin Ther; 2008 Oct; 30(10):1806-16. PubMed ID: 19014836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetic investigation of low-dose methotrexate in rheumatoid arthritics Japanese patients.
    Yukawa E; Mori S; Ueda K; Nakada Y
    J Clin Pharm Ther; 2007 Dec; 32(6):573-8. PubMed ID: 18021334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis.
    Hoekstra M; Haagsma C; Neef C; Proost J; Knuif A; van de Laar M
    J Rheumatol; 2006 Mar; 33(3):481-5. PubMed ID: 16463431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis.
    Vakily M; Amer F; Kukulka MJ; Andhivarothai N
    J Clin Pharmacol; 2005 Oct; 45(10):1179-86. PubMed ID: 16172183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.
    Emery P; Fleischmann R; Filipowicz-Sosnowska A; Schechtman J; Szczepanski L; Kavanaugh A; Racewicz AJ; van Vollenhoven RF; Li NF; Agarwal S; Hessey EW; Shaw TM;
    Arthritis Rheum; 2006 May; 54(5):1390-400. PubMed ID: 16649186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs.
    Popa C; Leandro MJ; Cambridge G; Edwards JC
    Rheumatology (Oxford); 2007 Apr; 46(4):626-30. PubMed ID: 17189244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis.
    Mould DR; Davis CB; Minthorn EA; Kwok DC; Elliott MJ; Luggen ME; Totoritis MC
    Clin Pharmacol Ther; 1999 Sep; 66(3):246-57. PubMed ID: 10511060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.
    Higashida J; Wun T; Schmidt S; Naguwa SM; Tuscano JM
    J Rheumatol; 2005 Nov; 32(11):2109-15. PubMed ID: 16265687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
    Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM
    Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial.
    Mease PJ; Revicki DA; Szechinski J; Greenwald M; Kivitz A; Barile-Fabris L; Kalsi J; Eames J; Leirisalo-Repo M
    J Rheumatol; 2008 Jan; 35(1):20-30. PubMed ID: 18050385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B cell depletion in early rheumatoid arthritis: a new concept in therapeutics.
    Renato GM
    Ann N Y Acad Sci; 2009 Sep; 1173():729-35. PubMed ID: 19758222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis.
    Roll P; Palanichamy A; Kneitz C; Dorner T; Tony HP
    Arthritis Rheum; 2006 Aug; 54(8):2377-86. PubMed ID: 16869000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Administration of monoclonal antibodies to B-lymphocytes (rituximab) in rheumatoid arthritis in Russia].
    Nasonov EL; Lukina GV; Sigidin IaA; Bazevich LA; Zlobina TI; Kamalova RG; Kniazeva LA; Mazurov VI; Men'shikova LV; Sizikov AE; Smirnova EA; Fofonova NA; Shabalina TV; Shkil' NV; Iakushin SS
    Ter Arkh; 2008; 80(8):57-62. PubMed ID: 18807543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.